Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30359094 | 0.79 | NISCH (0.42) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL30519171 | 0.79 | HDAC6 (0.45) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL674010 | 0.79 | NISCH (1.00) | NISCHALDH1A1KDM4EMTORADK | |
| 2-Phenylimidazole SCHEMBL29356009 | 0.79 | NISCH (0.63) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL27974204 | 0.78 | NISCH (0.96) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL28110769 | 0.78 | NISCH (0.96) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL28230038 | 0.78 | NISCH (0.96) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL27451043 | 0.78 | NISCH (0.96) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL722191 | 0.66 | NISCH (0.78) | NISCHALDH1A1KDM4EMTORADK | |
| SCHEMBL29446956 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885ALDH1A1 209/4885KDM4E 1179/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885ALDH1A1 209/4885KDM4E 1179/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885ALDH1A1 209/4885KDM4E 1179/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885ALDH1A1 209/4885KDM4E 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.